Overview

A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]

Status:
Terminated

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

Part A of this study will investigate the Maximum Tolerated Dose of Debio 0932 in combination with standard of care chemotherapy for the first- and second-line treatment of advanced NSCLC.

Phase:

Phase 1

Details

Lead Sponsor:

Debiopharm International SA

Collaborators:

INC Research
Syneos Health

Treatments:

Cisplatin
Docetaxel
Gemcitabine
Pemetrexed